Soleno’s Potassium Channel Agent Approved by FDA
- Food and Drug Management (FDA) has approved Soleno Therapeutics' Vykat XR (Diazoxide Choline extended-release), a potassium channel activator (PCA), for the treatment of hyperphagia in patients aged four...
- The approval, announced last month, marks the first commercially licensed treatment specifically targeting the overeating symptoms associated with PWS, a rare genetic disorder.
- According to Soleno Therapeutics, Vykat XR works by activating ATP-sensitive potassium (KATP) channels in the hypothalamus, a region of the brain that regulates appetite.
Soleno therapeutics’ Vykat XR Receives FDA Approval for Prader-Willi Syndrome Hyperphagia
Table of Contents
- Soleno therapeutics’ Vykat XR Receives FDA Approval for Prader-Willi Syndrome Hyperphagia
- Vykat XR for Prader-Willi Syndrome: Your Questions Answered
- What is Vykat XR?
- What is Prader-Willi Syndrome (PWS)?
- What are the main challenges faced by individuals with PWS?
- What does Vykat XR do in the body?
- How does Vykat XR help with hyperphagia?
- Why is this FDA approval significant?
- What treatments were used before Vykat XR for hyperphagia?
- What are the potential side effects of Vykat XR?
- how is Vykat XR administered?
- Where can I find more information?
WASHINGTON D.C. – The U.S. Food and Drug Management (FDA) has approved Soleno Therapeutics’ Vykat XR (Diazoxide Choline extended-release), a potassium channel activator (PCA), for the treatment of hyperphagia in patients aged four and older with Prader-Willi syndrome (PWS).
The approval, announced last month, marks the first commercially licensed treatment specifically targeting the overeating symptoms associated with PWS, a rare genetic disorder. Hyperphagia, or excessive eating, is considered one of the most significant challenges for individuals with PWS.
Mechanism of Action
According to Soleno Therapeutics, Vykat XR works by activating ATP-sensitive potassium (KATP) channels in the hypothalamus, a region of the brain that regulates appetite. This mechanism is believed to help control the urge to overeat. The drug also stimulates KATP channels in pancreatic beta cells,which leads to the suppression of insulin secretion. Vykat XR is administered orally once daily.
Unmet Need Addressed
Prior to this approval, there were no FDA-approved medications specifically indicated for the treatment of hyperphagia in PWS patients. Growth hormone (GH) has been used to manage muscle mass and body fat, while anti-seizure medications like topiramate have sometimes been prescribed off-label for weight loss.
About Prader-Willi Syndrome
Prader-Willi Syndrome is a rare genetic disorder that affects many parts of the body. Most people with PWS feel constantly hungry (hyperphagia), which can easily lead to perilous weight gain and type 2 diabetes.
Vykat XR for Prader-Willi Syndrome: Your Questions Answered
What is Vykat XR?
Vykat XR (Diazoxide Choline extended-release) is a new prescription medication approved by the U.S.Food and Drug Management (FDA). It’s designed to treat hyperphagia, or excessive hunger, in individuals aged four and older with Prader-Willi syndrome (PWS).
What is Prader-Willi Syndrome (PWS)?
Prader-Willi syndrome (PWS) is a rare genetic disorder affecting various parts of the body. A key characteristic of PWS is hyperphagia, meaning people with PWS experience a constant, insatiable hunger.
What are the main challenges faced by individuals with PWS?
Hyperphagia is one of the most significant challenges for people with PWS. This constant hunger can easily lead to:
Perilous weight gain
Type 2 diabetes
What does Vykat XR do in the body?
Vykat XR works by:
Activating ATP-sensitive potassium (KATP) channels in the hypothalamus, the part of the brain that regulates appetite. This helps control the urge to overeat.
Stimulating KATP channels in pancreatic beta cells, leading to the suppression of insulin secretion.
Vykat XR is administered orally once daily.
How does Vykat XR help with hyperphagia?
By targeting the hypothalamus, Vykat XR aims to reduce the constant feeling of hunger that’s a hallmark of PWS, helping to manage the excessive eating associated with the condition.
Why is this FDA approval significant?
The FDA’s approval of Vykat XR marks the frist commercially licensed treatment specifically for the overeating symptoms linked to PWS. Previously,there were no FDA-approved medications specifically for hyperphagia treatment in individuals with PWS.
What treatments were used before Vykat XR for hyperphagia?
Before this approval, doctors used other methods to manage symptoms. These include:
growth hormone (GH), used to help manage body fat and muscle mass.
Anti-seizure medications like topiramate, sometimes prescribed off-label for weight loss.
What are the potential side effects of Vykat XR?
This facts is not available in the provided text.
how is Vykat XR administered?
Vykat XR is administered orally, once daily.
Where can I find more information?
This information is not available in the provided text.